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The novelty of the subject. Healthcare-associated infections (HAIs) have become one of 
the major public health problems from the clinical, epidemiological and socio-economic 
perspectives. They represent a special chapter of pathology highlighted in the context of modern 
medical advances, determined by the diversity of diagnostic and therapeutic maneuvers, also due 
to the irrational use of antibiotics, especially the broad-spectrum ones, which leads to the selection 
of resistant bacteria [1, 2, 3, 4, 5]. 
Healthcare-associated infections caused by antibiotic-resistant microorganisms are one of 
the most important challenges for modern medicine today. A large part of Staphylococcus aureus 
infections are produced by a microbial pathogen resistant to a wide range of antibiotics used in the 
hospital environment, namely, methicillin-resistant Staphylococcus aureus (MRSA) [6]. 
From the first cases of MRSA to date, the problem has increased dramatically, the incidence 
of MRSA infections reaching endemic proportions in some hospitals. In Europe, a north-south 
gradient is observed, MRSA strains being rare in Scandinavian hospitals (<2%) and much more 
widespread in hospitals in Mediterranean countries (> 40%) [7, 8, 9]. 
Although in recent years the percentage of methicillin-resistant Staphylococcus aureus 
strains has decreased in the European Union / European Economic Area (EU / EEA), from 19.6% 
in 2014 to 16.9% in 2017, however, MRSA remains an important challenge at the European level, 
with high MRSA levels in several countries and an increased overall antimicrobial resistance [10, 
11, 12, 13]. 
In 2017, the World Health Organization (WHO) established the most important categories 
of multidrug-resistant germs, which required the introduction of new therapeutic options with 3 
priority levels: critical, high and medium; methicillin-resistant Staphylococcus aureus strains 
belonging to the high level [14, 15]. 
Shortly after the emergence of MRSA, it was realized that the problem of methicillin 
resistance involves not only coagulase-positive staphylococci (CPS), but also coagulase-negative 
staphylococci (CNS). Although in the beginning, these species of microorganisms were given little 
importance, being considered part of the normal flora of the skin and nasal mucosa, today, due to 
their resistance to antibacterial preparations, they have become a source of concern for the medical 
system. They are especially associated with the use of foreign bodies, implants, etc., which are 
indispensable in modern medicine [16, 17]. Increased rates of antibiotic resistance have been 
shown to be even a greater problem for CNS than for Staphylococcus aureus, limiting the treatment 
options [18, 19]. 
Methicillin resistance has been shown to have a negative impact on clinical and economic 
outcomes, especially in terms of increased morbidity and mortality and long-term hospitalization, 
as well as the need for additional interventions to mitigate the clinical impact [20, 21, 22, 23, 24, 
25]. 
The ranking of staphylococci first in the etiology of bacterial infections, the annual increase 
in the number of methicillin-resistant staphylococcal strains and the emergence of strains resistant 
to spare antistaphylococcal antibiotics, place this medical condition among emerging infectious 
diseases [26, 27, 28, 29]. 
In the Republic of Moldova, studies on the incidence of infections caused by methicillin-
resistant Staphylococcus (MRS) are fragmentary [28, 29, 30]. 
Knowledge of local epidemiology of methicillin-resistant Staphylococcus infections will 
contribute to raising the awareness of the problem and implementation of rational measures for 





To study the epidemiology of nosocomial infections caused by methicillin-resistant 
Staphylococcus in the Republic of Moldova in order to optimize the surveillance and control 
system. 
Research objectives 
1. To determine the share of purulent-septic infections (PSIs) with methicillin-resistant 
Staphylococcus in the Republic of Moldova, based on general hospitals, maternity wards and 
healthcare settings in rural areas, and to carry out a comparative analysis. 
2. To determine the epidemiological peculiarities, as well as the risk factors in purulent-
septic infections caused by MRS. 
3. To determine the degree of susceptibility/resistance of MRS strains isolated from patients 
with purulent-septic infections depending on the group and type of antibiotic. 
4. To determine the medical and socio-economic impact of purulent-septic infections with 
MRS. 
Scientific novelty  
Studies on PSI epidemiology caused by MRS have been carried out internationally. At the 
national level, for the first time a complex epidemiological study was conducted on the 
epidemiology of PSIs caused by MRS and the level of spread was determined. 
Theoretical significance and applied value of the work: 
1. The rate of PSIs caused by MRS has become known, as well as the epidemiological 
peculiarities depending on the profile of inpatient departments in the Republic of Moldova. 
2. The risk factors and the socio-economic impact of the PSIs produced by MRS were 
determined. 
3. The degree of sensitivity / resistance of the MRS strains was determined, depending on 
the group and type of antibiotic. 
4. Measures were proposed to optimize the surveillance and control of PSIs caused by MRS 
in healthcare settings. 
Practical implementation of results 
1. The research results were implemented within the Department of Preventive Medicine, 
Discipline of Epidemiology, as teaching material for graduate and postgraduate training of doctors 
as well as in the scientific laboratory " Intrahospital infections" 
2. Two scientific-practical seminars on "The problem of spread and antibiotic resistance of 
nosocomial infections with methicillin-resistant Staphylococcus" were organized within the Public 
Health Care Setting (PHCS) of the Republican Clinical Hospital "Timofei Moşneaga" 
(03.02.2021) and PHCS Emergency Medicine (19.02.2021). 
3. The study results will complete the next edition of the "Guide to surveillance and control 
of nosocomial infections". 
4. The results obtained were presented in scientific papers at 16 scientific forums, as well as 
in 15 scientific publications. 
 
Approval of results 
● National Scientific Conference with international participation “Optimizing epidemiological 
surveillance in nosocomial infections”, October 13-14, 2017, Chisinau, Republic of 
Moldova. 
● Annual scientific conferences of Nicolae Testemitanu SUMPh students and teaching staff, 




● Всероссийская научно-практическая конференция специалистов по контролю ИСМП 
"Инфекции, связанные с оказанием медицинской помощи - междисциплинарный 
подход к профилактике" с международным участием, 24-25 апреля 2019, 
Екатеринбург. 
● The scientific event dedicated to the U.M.Ph days in Craiova, the XLIXth edition, June 7-8, 
2019, Craiova, Romania. 
● The VIIIth Congress of specialists in the field of public health and health management, 
October 24-25, 2019, Chisinau, Republic of Moldova. 
● The XII National Conference on Microbiology and Epidemiology "Romanian Microbiology 
and Epidemiology - Achievements, Evolutions and Perspectives", November 14-16, 2019, 
Bucharest, Romania. 
● International Congress of Students and Young Research Doctors "MedEspera-2020", 8th 
edition, September 24-26, 2020, Chisinau, Republic of Moldova. 
● Ежегодная всероссийская научно-практическая конференция с международным 
участием "Актуальные проблемы эпидемиологии инфекционных и неинфекционных 
болезней 2020", 21-23 октября 2020, Москва. 
● Congress dedicated to the 75th Anniversary of the Nicolae Testemitanu SUMPh founding, 
October 20-23, 2020, Chisinau, Republic of Moldova. 
● The European Researchers' Night 2020, Chisinau, November 27, 2020. 
● The scientific-practical seminar “The problem of spread and antibiotic resistance of 
nosocomial infections with Acinetobacter and methicillin-resistant Staphylococcus” within 
the PHCS of the Republican Clinical Hospital “Timofei Moșneaga”, February 3, 2021. 
● The scientific-practical seminar “The problem of spread and antibiotic resistance of 
nosocomial infections with Acinetobacter and methicillin-resistant Staphylococcus” within 
PHCS Institute of Emergency Medicine, February 19, 2021. 
● National Scientific Conference with International Participation “Infectious Diseases in the 
Modern World: Challenges and Perspectives”, March 26, 2021, Chisinau, Republic of 
Moldova. 
 
The thesis was discussed, approved and recommended for defense at the joint meeting of the 
academic staff of the Discipline of Epidemiology and the Scientific Laboratory "Intrahospital 
Infections" of 14.09.21 (minutes no. 3), at the meeting of the Scientific Seminar 331. Public 
Health, 333 Occupational health and biomedicine / 331.01. Epidemiology, 331.02. Hygiene, 
333.01 Occupational hygiene, of 26.10.21 (minutes no. 4), and finally, within the Consortium 
Council of Nicolae Testemitanu State University of Medicine and Pharmacy of 02.12.2021 
(minutes no. 25). 
Research methodology and study design were evaluated and approved by Nicolae 
Testemitanu SUMPh Research Ethics Committee, no. 46 of 12.04.2018. 
Publications 
Based on the thesis materials, 15 scientific papers were published, of which, 5 in impact 
factor journals and 4 articles in national journals, including 2 single-authored articles, as well as 6 








Subdivisions and institutions within which the research was conducted 
The research was carried out in the Scientific Laboratory "Intrahospital Infections" under 
the program: 15.817.04.03F "Study on nosocomial infections with Acinetobacter, Pseudomonas 
and methicillin-resistant Staphylococcus  between 2015 and 2018", based on bacteriological 
investigations of patients with purulent-septic infections from two healthcare settings (PHCS 
Institute of Emergency Medicine, PHCS Republican Clinical Hospital "Timofei Moşneaga"), a 
maternity ward (PHCS Municipal Clinical Hospital "Gheorghe Paladi"), as well as rural healthcare 
settings (on the model of three districts: Criuleni, Strașeni and Ialoveni, bacteriological 
investigations  being carried out in the bacteriology laboratory within the Public Health Center, 
Chisinau). 
Keywords: Healthcare-associated infections, purulent-septic infections, methicillin-
resistant Staphylococcus, methicillin-susceptible Staphylococcus, clinical forms, antibiotic 





General characteristics of the research group 
The study was performed based on the retrospective descriptive epidemiological study of 
the results of bacteriological investigations of patients with purulent-septic infections caused by 
methicillin-resistant Staphylococcus from two healthcare settings (PHCS Republican Clinical 
Hospital "Timofei Moșneaga" (inpatient department no. 1) and PHCS Institute of Emergency 
Medicine (inpatient department no. 2) for a period of 4 years (2014-2017), the share of MRS strains 
in the multiannual dynamics being determined for the period 2014-2019; of patients from 
healthcare settings in rural areas (on the model of three districts, Criuleni, Ialoveni, Straseni) and 
maternity wards (maternity ward within the PHCS of the Municipal Clinical Hospital "Gheorghe 
Paladi"), 2017. 
A total of 13,219 staphylococcal strains were analyzed, 11,803 being isolated from 
healthcare settings, 1,090 from rural areas and 326 from maternity wards. Methicillin-resistance 
of Staphylococcus strains was established depending on the resistance to oxacillin (2014-2017) 
and cefoxitin (2018-2019), which was determined by using the disc-diffusion test (Kirby-Bauer) 
and the automatic microbiological analyzer VITEK 2 Compact in the healthcare settings. Only the 
disc-diffusion test was used in the PHCS Municipal Clinical Hospital "Gheorghe Paladi" and in 
the rural environment. The results were interpreted according to the standard recommendations of 
CLSI (Clinical and Laboratory Standards Institute) and EUCAST (European Committee on 
Antimicrobial Susceptibility Testing). 
In order to determine the risk factors, the antibacterial management and the socio-economic 
impact, the data from the patient's medical records with PSIs caused by methicillin-resistant 
staphylococci were analyzed. The basic group was made up of patients with bacteriological 
investigations positive for methicillin-resistant Staphylococcus (MRS), while the control group 
comprised patients with positive bacteriological investigations for methicillin-sensitive 
Staphylococcus (MSS). The study included all patients with septicemia, trophic ulcers, 





In this context, 462 patients' medical records were retrospectively analyzed, 269 medical 
records of patients with nosocomial purulent-septic infections with MRS and 193 medical records 
of patients with nosocomial purulent-septic infections with MSS. 
In order to achieve the purpose and objectives set, the general design of the research has 




















Figure 1. Research design 
Research methods applied in the study 
Microbiological methods 
Staphylococcal strains were isolated, as well as antibiotic sensitivity / resistance was 
determined in the medical laboratories under study, using the classical method, described by 
Galețchi P. et al. (1997), Buiuc D. (2009), and the automated system VITEK 2 Compact 
(bioMérieux) [31, 32, 33]. 
 
Epidemiological methods 
The epidemiological method was used to study and to describe the morbidity of purulent-
septic infections caused by MRS, as well as to calculate the degree of antibiotic sensitivity / 
resistance, antibacterial management, risk factors and socio-economic impact. The determination 
1. Retrospective descriptive study 
Records of the bacteriological investigation results of patients with purulent-




 Assessment of the evolution share of methicillin-resistant Staphylococcus strains of the total number of 
Staphylococcus strains, epidemiological peculiarities and the degree of sensitivity / resistance to antibiotics 
 
și   
2. Case-control study 




Basic group - patients with nosocomial 
purulent-septic infections caused by 
MRS (n = 269) 
 
 Control group - patients with 
nosocomial purulent-septic infections 
caused by MSS (n = 193) 
 
  
Epidemiological assessment of risk factors and antibacterial management in MRS infections 
Assessment of medical and socio-economic impact  
 
 




of epidemiological features and the degree of antibiotic susceptibility / resistance of MRS 
infections refers to descriptive observational epidemiological studies and is based on the method 
of retrospective analysis according to the methodology described by Prisacari Viorel in “General 
Epidemiology. Bases of evidence-based medicine” (2020) [34]. 
 
Criteria for inclusion in the study: 
 all bacteriological investigations positive for MRS and MSS examined in the 
bacteriological laboratories of inpatient departments included in the study; 
Exclusion criteria from the study: 
 bacteriological investigations negative for MRS and MSS. 
The socio-economic impact and risk factors were determined in a retrospective case-control 
study, based on data from patients` medical records with PSIs caused by MRS, being compared 
with data from the medical records of patients with PSIs caused by MSS. 
The research groups were made according to the method described in “General 
Epidemiology. Bases of evidence-based medicine” (2020), patients with MRS being the exponents 
of the basic group, while patients with MSS constituted the control group. 
Statistical methods of data processing  
The results obtained were entered into electronic databases and statistically processed, 
using the computer programs WHONET 5.6, Microsoft Office Excel 2010 and IMB SPSS 
Statistics 22. 
 
SYNTHESIS OF THESIS CHAPTERS 
 
1. EPIDEMIOLOGY OF NOSOCOMIAL INFECTIONS WITH METHICILLIN-
RESISTANT STAPHYLOCOCCUS (LITERATURE REVIEW) 
Chapter I comprises the synthesis of the research results on MRS infections exposed in the 
literature, structured in 4 subchapters: the situation of healthcare associated infections with 
methicillin-resistant Staphylococcus worldwide, clinical and epidemiological aspects of MRS 
infections, antibiotic-resistance of MRS strains, risk factors and preventive measures in MRS 
infections. The analysis of the literature on the topic argues the need for this study. 
 
2.     RESEARCH MATERIAL AND METHODS 
Chapter II contains information on the research methodology. 
 
3. EPIDEMIOLOGY OF PURULENT-SEPTIC INFECTIONS WITH METHICILLIN-
RESISTANT STAPHYLOCOCCUS IN THE REPUBLIC OF MOLDOVA 
3.1. Spread of purulent-septic infections with methicillin-resistant Staphylococcus in 
healthcare settings 
The incidence of Staphylococcus strains in the etiology of PSIs in healthcare settings 
according to the study results makes up - 24.2%. 
During 2014 – 2019, in the two healthcare settings, under the study, 11,803 staphylococcal 
strains were isolated from patients with purulent-septic infections, of which 10,861 (92.0%), were 
tested to susceptibility / resistance to oxacillin / cefoxitin. As a result, it was found that the share 
of methicillin-resistant Staphylococcus strains in healthcare settings is on average 40.5% (95 % CI 





Table 1. Share of MRS and MSS strains in the total number of staphylococcal 




 Isolated strains (total) Strains tested to 
oxacillin* / cefoxitin ** 
including 
resistant (MRS) 
abs % (95% CI) abs % (95% CI) abs % (95% IC) 
Inpatient 
department no.1 6510 
 
55.2 (54.3-56.1) 5940 91.2 (90.6-92.0) 2375 40.0 (38.7-41.2) 
Inpatient 
department no. 2 5293 
 
44.8 (43.9-45.7) 4921 93.0 (92.2-93.6) 2022 41.0 (39.7-42.5) 
Total 11 803 100.0 10 861 92.0 (91.6-92.5) 4397 40.5 (39.6-41.4) 
 
*2014 – 2017 – methicillin-resistance determined by resistance to oxacillin 
** 2018 – 2019 – methicillin-resistance determined by resistance to cefoxitin 
 
 
In the multiannual dynamics, the issue of PSIs caused by MRS in healthcare settings is 
getting worse. The share of MRS strains isolated from patients with PSIs during 6 years of study 




Figure 2. Share of MRS strains in the total number of Staphylococcus strains in 
multiannual dynamics 
 
The study found that both coagulase-positive staphylococci and coagulase-negative 
staphylococci are likely to obtain resistance to methicillin. 
 
Figure 3. Share of methicillin-resistant Staphylococcus strains in multiprofile hospitals, 












































Of the total number of coagulase-positive Staphylococcus strains (S. aureus) tested for 
susceptibility / resistance to oxacillin / cefoxitin (n = 5410), resistance accounted for 21.2% (95% 
CI 20.2-22.4). A much higher degree of resistance to oxacillin / cefoxitin was found in coagulase-
negative Staphylococcus strains. S. hominis strains showed resistance to oxacillin / cefoxitin in 
82.5% (95% CI 75.5-88.8) cases, S. epidermidis - in 64.6% (95% CI 62.4-66.7), S. haemolyticus - 
in 57.4% (95% CI 55.5-59.2), S. saprophyticus - in 48.9% (95% CI 44.8-53.0). Other species of 
coagulase-negative staphylococci isolated in smaller shares (S. capitis, S. sciuri, S. warneri, S. 
lugdunensis) showed resistance in 63.5% (95% CI 53.1-73.1) (figure 3). 
The level of MRS spread also varies depending on the department profile. More affected by 
MRS were: departments of traumatology and orthopedics 49.4% (95% CI 46.4-52.5) – inpatient 
department no. 2; department of surgery 32.2% (95% CI 29,7-34,9) – inpatient department no.1 
and 34,9% (95% CI 32,1-37,9) – inpatient department no. 2; anesthesia and intensive care - 23.6% 
(95% CI 21.3-26.1) – inpatient department no. 1 and 12.6% (95% CI 10.7-14.8) – inpatient 
department no. 2. In both settings, there was a significantly high level of isolation of MRS strains 
from outpatients 21.1% (95% CI 19.1-23.2) – inpatient department no. 1 and 7.2% (95% CI 5,7-
8,8) – inpatient department no. 2. 
Depending on the pathological material from which they were isolated, staphylococcal 
strains showed a varying methicillin resistance. An obviously high share of MRS was found in 
blood cultures. Thus, of the total number of staphylococcal strains isolated from blood (n = 201), 
153 strains were methicillin-resistant, accounting for 76.1% (95% CI 69.6-81.8). Also, 
staphylococcal strains isolated from the bile showed increased oxacillin resistance - 48.5% (95% 
CI 42.9-54.0). Staphylococcal strains isolated from urogenital tract samples showed oxacillin 
resistance in 22.9% (95% CI 19.4-26.8) and 16.7% (95% CI 14, 6-18,9) in respiratory samples. 
The high share of MRS strains isolated from the blood is a serious issue, accounting for 
generalized infections (pneumonia, septicemia, etc.). Of the total number of patients with PSIs 
caused by methicillin-resistant Staphylococcus, 62.3% (56.9-67.9) had generalized infections, 
including pulmonary sepsis (25.3%, 95% CI 20,5-30.5), abdominal sepsis (21.5%, 95% CI 17.0-
26.5), skin sepsis (7.4%, 95% CI 4.7-10.9), urosepsis (8.3%, 95% CI 5.5-12.0), and only 37.8% 
(95% CI 32.1-43.1) had localized forms, including inflammation / lung damage (9.0%, 95% CI 
6.0-12.7), infected wounds (14.7%, 95% CI 11.0-19.2), spondyloarthritis (13.8%, 95% CI 10.2-
18.1 ). 
The MRS strains isolated in association with other species of microorganisms are of 
epidemiological and clinical significance. The analysis of the bacteriological results of the 
pathological materials, collected from patients with purulent-septic infections in multiprofile 
hospitals, found that MRS strains in 62.0% (95% CI 51.7-71.5) of cases were isolated in 
monocultures, and 38.0% (95% CI 28.6-48.4) of cases - in associations with other species of 
microorganisms. Associations with a single species of microorganisms constituted - 25.5% (95% 
CI 17.3-35.2), with two species of microorganisms - 10.9% (95% CI 5.5-18.7) and associations 
with 3 species of microorganisms were found in 1.7% (95% CI 0.2-6.6) of cases, which greatly 
complicates the course of diseases caused by MRS. 
 
3.2. Spread of purulent-septic infections with methicillin-resistant Staphylococcus in 
maternity wards 
The study revealed a high share of MRS strains in the maternity ward. Of the total number 




CI 56.1-67.3) of strains were oxacillin resistant (MRS), and only 38.2% (95% CI 32.7-43.9) strains 
were oxacillin susceptible (MSS). 
 
Table 2. Share of MRS strains in the total number of Staphylococcus strains isolated 









to oxacillin  
including 
resistant (MRS) sensitive (MSS) 
abs abs % abs % (95% CI) abs % (95% CI) 
S. aureus 124 124 100.0 54 43.5 (34.7-52.7) 70 56.5 (47.3-65.3) 
S. epidermidis 202 185 91.6 137 74.1 (67.1-80.2) 48 25.9 (19.8-32.9) 
Total 326 309 94.8 191 61.8 (56.1-67.3) 118 38.2 (32.7-43.9) 
 
3.3. Spread of purulent-septic infections with methicillin-resistant Staphylococcus in rural 
healthcare settings 
 
In terms of the spread of methicillin-resistant Staphylococcus strains in rural healthcare 
settings, it was found that the share of methicillin-resistant Staphylococcus strains averaged out to 
22.4% (95% CI 19.5-25.4). 
 
 







 Administrative territory 
Criuleni Ialoveni Strașeni Total 
Isolated strains 
(total) 
abs 316 490 284 1090 
Strains tested to 
oxacillin 

















































In Strașeni district, of the total number of Staphylococcus strains isolated from patients with 
PSIs, oxacillin-resistant staphylococcal strains constituted 26.9% (95% CI 20.9-33.6), in Criuleni 
district - 26.5% (95% CI 20.6-33.1) and 17.8% (95% CI 14.1-22.0) in Ialoveni district (table 3). 
 
 
3.4. Assessment of the level of spread of methicillin-resistant Staphylococcus strains in the 
Republic of Moldova 
Of the total of 13 219 Staphylococcus strains isolated from patients with purulent-septic 




average level of spread of methicillin-resistant Staphylococcus strains in the Republic of Moldova 
was determined, accounting for 39.8% (95% CI 38.9-40.7). 
 
 
Figure 4. The level of spread of methicillin-resistant Staphylococcus strains in the 
Republic of Moldova 
 
The epidemiological study found significant differences between the spread of methicillin-
resistant Staphylococcus strains in multiprofile hospitals and the living environment. The highest 
frequency of MRS isolation was found in maternity wards 61.8% (95% CI 56.1-67.3), followed 
by multiprofile hospitals - 40.5% (95% CI (39.6-41.4). A lower frequency of 22.4% (95% CI 19.5-
25.4) of MRS isolation was found in patients in rural healthcare settings (figure 4). 
 
4. ANTIBIOTIC RESISTANCE/ MULTI-DRUG RESISTANCE OF METHICILLIN-
RESISTANT STAPHYLOCOCCUS STRAINS 
4.1. Antibiotic resistance of methicillin-resistant Staphylococcus strains 
Analysis of antibioticograms of MRS strains isolated from patients with PSIs found a high 
share of antibiotic resistance. Antimicrobial resistance of methicillin-resistant Staphylococcus 
strains varied with both the group of antibiotics and the type of antibiotics. According to EUCAST 
(European Committee on Antimicrobial Susceptibility Testing), methicillin-resistant 
Staphylococcus strains (oxacillin / cefoxitin resistant) are resistant to beta-lactam antibiotics, a fact 
observed in the study.  
The resistance of MRS strains to non-beta-lactam antibiotics has varied. The strains isolated 
from healthcare settings showed a higher degree of resistance to macrolides, fluoroquinolones, 
lincosamides, aminoglycosides, tetracyclines, phenicols, and higher susceptibility to 
glycopeptides, oxazolidinones, sulfamides (figure 5A). 
Although the share of MRS strains in the maternity ward is quite high, the spectrum of 
antibiotics to which the susceptibility / resistance is tested is quite narrow, the strains also show a 
high degree of resistance to antibiotics tested (figure 5B). 
The MRS strains isolated in rural healthcare settings showed a high resistance to macrolides, 
tetracyclines, sulfamides, aminoglycosides, phenicols, and an increased susceptibility to 






















Figure 5. Resistance to non-beta-lactam antibiotics of MRS strains isolated from patients 
with PSIs in multi-profile hospitals (A), maternity ward (B) and rural area (C) 
4.2. Multi-drug resistance of methicillin-resistant Staphylococcus strains 
The MRS strains isolated from patients with PSIs were found to be multi-drug resistant to 
antibiotics - 76.2% (95% CI 74.6-77.8) (figure 6). The analysis of multi-drug resistance of MRS 
strains in the multiannual dynamics accounts for an alarming situation. Thus, multi-drug resistance 
of MRS strains increased from 79.0% (95% CI 75.8-81.9) in 2014 to 89.9% (95% CI 87.3-92.1) 
in 2017 (figure 7). 
 
















































4.3. Antibiotic resistance of Staphylococcus strains isolated from blood 
The study of antibiograms of MRS and MSS blood cultures isolated from patients with sepsis 
found an increased antibacterial resistance of MRS strains, compared to MSS strains that showed, 





Figure 8. Resistance / susceptibility to non-beta-lactam antibiotics of MRS (I) and MSS (II) 
strains isolated from patients with septicemia 
 
5. RISK FACTORS, ANTIBACTERIAL MANAGEMENT AND SOCIO-ECONOMIC 
IMPACT IN PSIs WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS 
5.1. Risk factors in PSIs with methicillin-resistant Staphylococcus 
Table 4. Comparative assessment of risk factors in MRS infections 
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The comparative assessment of risk factors in MRS infections found that the risk factors 
which greatly complicate the clinic and treatment of patients, were as follows: microbial 
associations RR (OR) - 4.8 (95% CI 3.2 – 7.3), treatment exposure in ICU RR (OR) - 4.5 (95% CI 
3.0 - 6.7), repeated hospitalizations RR (OR) - 3.2 (95% CI 2.2 - 4.7), the presence of surgeries 
RR (OR) - 1.4 (95% CI 1.0 - 2.1), emergent hospitalizations RR (OR) - 1.4 (95% CI 1.0 - 2.1), and 
people over the age of 50  RR (OR) - 1.3 (95% CI 1.0 - 1.9) (table 4). 
 
5.2. Antibacterial therapeutic management of patients with methicillin-resistant 
Staphylococcus infections 
Based on table 5, which summarizes the antibacterial therapeutic management of patients 
with MRS and MSS, it was found that patients with PSIs with MRS were administered from 1 to 
9 antimicrobial preparations as part of antimicrobial therapy. After comparing the resistance 
/susceptibility of MRS strains in patients receiving antibiotic therapy, using antibioticograms, it 
was found that in 53.2% (95% CI 49.7-56.7) MRS strains proved to be resistant to administered 
antibiotics, 24.7% (95% CI 21.7-27.8) of cases were not tested for susceptibility / resistance, and 
only in 22.1% (95% CI 19.3-25.2) of cases isolated strains showed susceptibility to administered 
antibiotics. On average, only one patient received 3 antimicrobial preparations. 
 
Table 5. Number of antibiotics administered to a patient with MRS in monocultures 
and microbial associations, including antimicrobial resistance / susceptibility 
  of MRS strains 
 
Number of administered 
antibiotics  
0 1 2 3 4 5 6 7 8 9 Total 
Research group (MRS) 
Number of 
patients 
abs 5 54 58 63 41 28 14 1 4 1 269 
% 1.9 20.1 21.6 23.4 15.2 10.4 5.2 0.4 1.5 0.4 100.0 
Total administered 
antibiotics  












- 32 63 103 90 75 45 3 11 1 423 
% - 59.3 54.3 54.5 54.9 53.6 53.6 42.9 34.4 11.1 53.2 
S ab
s 
- 6 25 40 38 34 15 2 13 3 176 






- 16 28 46 36 31 24 2 8 5 196 
% - 29.6 24.1 24.3 22.0 22.1 28.6 28.6 25.0 55.6 24.7 
Control group (MSS) 
Number of 
patients 
abs 7 102 54 18 7 3 2 - - - 193 
% 3.6 52.8 28.0 9.3 3.6 1.6 1.0 - - - 100.0 











- 1 1 - 1 - - - - - 3 
% - 1.0 0.9 - 3.6 - - - - - 0.9 
S ab
s 
- 81 86 46 18 13 11 - - - 255 






- 20 21 8 9 2 1 - - - 61 






In terms of the therapeutic management of patients with MSS infections, it proved to be 
much more effective, as MSS strains showed resistance to antimicrobial preparations administered 
only in 0.9% (95% CI 0.2-2.7) and, conversely, susceptibility in 79.9% (95% CI 75.1-84.2). 
Patients with MSS were administered a smaller number of antibiotics, compared to those with 
MRS, from 1 to 6 antibiotics. On average, only one patient received 1.7 antimicrobial preparations 
(table 5). 
 
5.3. Socio-economic impact of infections caused by methicillin-resistant Staphylococcus 
strains 
Based on table 6, which summarizes the impact of patients compared to the number of MRS 
and MSS infections, according to the main criteria (number of hospital bed days, expenses per 
patient, lethality rate), the situation is much more serious in patients with MRS, differences 
between hospital bed days (19.5 days vs 12.8 days) and expenses (11 272 lei vs 7530 lei per 
patient), the lethality rate (20.4% vs 4.1%) being significant in the groups of patients with MRS 
and MSS. 
Table 6. Mean comparative impact in MRS and MSS infections 
 
Nosological form 




Lethality rate (%) 
MRS MSS MRS MSS MRS MSS 
Septicemia 21.1 15.7 12 660 9 438 28.9 7.5 
Inflammation/lung 
damage 
18.3 11.3 11 010 6 780 8.6 2.5 
Trophic ulcers 16.9 10.6 10 146 6 372 7.7 1.4 
Mas (lots/groups of 
patients) 
19.5 12.8 11 272 7 530 20.4 4.1 
 
6. DISCUSSIONS 
Antimicrobial resistance is a global priority. According to the WHO, antimicrobial resistance 
has reached alarming levels in many regions of the world [14, 15]. The development of antibiotic 
resistance, including Staphylococcus strains, is one of the great challenges facing humanity today. 
Since the first reporting of methicillin resistance in Staphylococcus strains in 1961, to date, the 
scale of the problem has increased dramatically, and monitoring of variations in antibiotic 
sensitivity of Staphylococcus in different countries has become a mandatory concern.  
Studies found considerable variations in the level of spread of MRSA strains in European 
countries. A north-south gradient is observed, MRSA strains being rare in Scandinavian hospitals 
(< 2%) and much more widespread in hospitals in Mediterranean countries (> 40%) [7, 8, 9]. 
In most EU / EEA countries, as a result of implemented intervention programs to limit the 
incidence of severe MRSA infections, in recent years the percentage of methicillin-resistant 
Staphylococcus aureus strains decreased from 19.6% in 2014 to 16.9% in 2017 [12, 13]. 
The study showed that methicillin-resistant Staphylococcus infections are a major public 
health problem in the Republic of Moldova. The level of spread of methicillin-resistant 
staphylococcal strains in the Republic of Moldova is high, averaging 39.8% (95% CI 38.9-40.7), 
and varies depending on the type of healthcare setting. The highest share is found in maternity 
wards 61.8% (95% CI 56.1-67.3), followed by healthcare settings 40.2% (95% CI (39.6-41.4), a 




In the multiannual dynamics, the share of methicillin-resistant Staphylococcus strains increased 
from 29.6% (95% CI 27.9-31.4) in 2014 to 55.9% (95% CI 53.4-58.4) in 2019, reaching high 
levels in blood cultures (76.1% (95% CI 69.6-81.8), as well as for coagulase-negative 
staphylococci (59.6% (95% CI 58.3-60.9). There is currently an alarming situation in the Republic 
of Moldova in terms of maintaining antimicrobial resistance, which imposes the need for 
emergency measures at all levels. Knowledge of local epidemiology in purulent-septic nosocomial 
infections with MRS will contribute to the implementation and provision of rational measures for 
surveillance and control of this issue. 
Methicillin resistance of Staphylococcus strains has a negative impact on clinical and 
economic outcomes. MRS infections significantly increase economic costs by prolonging 
hospitalization, enhancing incapacity for work, augmenting the use of antibiotics and other 
treatment methods, and increasing the need for additional diagnostic tests [20, 21, 22, 23, 24, 25]. 
The results obtained in the study show that in patients with MRS infections the duration of 
hospitalization is much longer compared to that of patients with MSS infections, and the 
antibacterial therapeutic management of MRS patients proved to be much more complicated, 
compared to patients with MSS, the latter requiring a complex treatment over a longer period, as 
well as a larger number of hospital stays, including in intensive care units. Also, the lethality rate 
of patients with purulent-septic infections caused by MRS is much higher compared to that of 
patients with MSS, reaching on average 20.4%, compared to 4.1%, which demonstrates both the 
severity and the relevance of the problem, as well as the need for implementing rational 
surveillance and control measures. 
 
THESIS CONCLUSIONS  
 
1. Nosocomial infections with MRS are currently a major public health problem. The level 
of spread of methicillin-resistant Staphylococcus strains in the Republic of Moldova constitutes 
on average 39.8% (95% CI 38.9-40.7) of the total Staphylococcus strains and varies depending on 
the type of healthcare setting. The highest share is found in maternity wards 61.8% (95% CI 56.1-
67.3), followed by healthcare settings 40.2% (95% CI (39.6-41.4), a lower level of spread of MRS 
is recorded in rural healthcare settings 22.4% (95% CI 19.5-25.4). In the multiannual dynamics 
the share of MRS strains increased from 29.6% (95% % CI 27.9-31.4) in 2014 to 55.9% (95% CI 
53.4-58.4) in 2019. 
2. The severity of the clinical forms is a peculiarity of nosocomial purulent-septic infections 
caused by MRS, the generalized forms being predominant 62.3% (56.9-67.9). The high rate of 
76.1% (95% CI 69.6-81.8) of methicillin-resistant Staphylococcus (MRS) strains in blood cultures 
confirms this fact. This phenomenon is largely favored by microbial associations - 38.0% (95% 
CI 28.6-48.4), thus greatly complicating both the clinical course and treatment of these infections. 
3. Although coagulase-positive staphylococcus is more common in human purulent-septic 
infections, the degree of methicillin resistance was found to be lower - 21.2% (95% CI 20.2-22.4), 
compared to coagulase-negative staphylococci - 59.6% (95% CI 58.3-60.9). 
4. The most affected departments by PSIs with MRS in multiprofile PHCS proved to be the 
following departments: traumatology and orthopedics, surgery, anesthesia and intensive care. At 
the same time, a large part of the MRS strains in both settings were isolated from patients in the 
consulting rooms as well as from patients receiving outpatient treatment, which demonstrates that 




5. It was found that MRS strains also show a much higher resistance to all groups of antibiotics 
compared to MSS strains. The investigations confirm a high resistance of MRS to beta-lactamases, 
and compared to non-beta-lactam antibiotics, the resistance of MRS strains varies depending on 
the group of antibiotics. 76.2% (95% CI 74.6-77.8) of the MRS strains proved to be multi-drug 
resistant to antibiotics. This index increased in the multiannual dynamics from 79.0% (95% CI 
75.8-81.9) in 2014 to 89.9% (95% CI 87.3-92.1) in 2017. 
6. Microbial associations, treatment in intensive care units, urgent and repeated hospitalizations, 
the presence of surgery and people over 50 years of age have been shown to be risk factors for 
MRS infections. 
7. Irational antibacterial management in the treatment of patients with MRS is an important 
phenomenon. Patients with MRS strains isolated in monocultures and microbial associations were 
indicated from 1 to 9 antibiotics, to which only 22.1% (95% CI 19.3-25.2) of the strains showed 
susceptibility. Although the resistance of MRS strains to cephalosporins is high, they continue to 
be used in the treatment of MRS infections. 
8. The socio-economic impact of patients with PSIs with MRS is much higher compared to 
patients with MSS, the latter requiring a more complex treatment over a longer period and a larger 
number of days of hospital stay. The consequences of MRS infections are much more serious, the 
lethality being about 5 times higher, compared to MSS infections, which accounts for both the 
severity and relevance of the problem. 
 
RECOMMENDATIONS 
1. Based on the current issue of accelerated spread and increased antibiotic resistance of 
methicillin-resistant Staphylococcus, it is necessary to intensify the surveillance of methicillin-
resistant Staphylococcus infections which should include assessment of the level of  MRS spread, 
detection, recording, monitoring and analysis of cases of MRS infections, systematic evaluation 
of antibiotic resistance of MRS strains, determination of risk factors and departments/units 
exposed to risk in all healthcare settings, implementation of strict surveillance and control 
measures, including the rational use of antibiotics. 
2. Upon the admission to the hospital, the patients transferred from other inpatient departments, 
as well as the patients with indications for complicated surgeries in case of planned hospitalizations 
require compulsorily to be subjected to the bacteriological investigation for MRS detection.  
3. It is practically impossible to effectively treat patients with NPSIs, especially caused by 
MRS, without any microbiological diagnosis which entails the use of an antibiogram. Hence, it is 
necessary to make the microbiological diagnosis more efficient as the main means in the 
surveillance and control of MRS infections by equipping microbiological laboratories with 
specialists, modern technology and other means necessary to ensure timely and qualitative 
microbiological diagnosis. The determination of MRS strains urgently requires an extended 
antibiogram to a wider spectrum of antibiotics, including those in the hospital reserve.  
4.The increasing resistance of MRS strains to several antimicrobial agents necessitates the 
prudent use of antibacterial preparations, in accordance with the individual results of antimicrobial 
susceptibility testing for isolated strains of each patient. 
5. In order to reduce the risk of dissemination and contamination of other patients, it is necessary 
to implement strict control measures, namely, to isolate patients with MRS in separate wards, 
specially designed for such patients, and to detect MRS carriers among patients upon admission 




6. Supplementing antibiotics as needed by healthcare settings, based on the results of studies 
on susceptibility / resistance of circulating strains in the setting, is mandatory. The rational use of 
antibiotics will make the treatment efficient and will reduce antibiotic resistance. 
 
REFERENCES 
1. Prisacari V. Ghid de supraveghere şi control în infecţiile nosocomiale. Chişinău, 2009; ed. 
II: 9-10; 27; 182. 
2. Prisacari V, Berdeu I. Problema antibioticorezistenței microbiene. Akademos. 2014; 1(32): 
92-100. 
3. European Centre for Disease Prevention and Control. Point prevalence survey of 
healthcareassociated infections and antimicrobial use in European acute care hospitals – 
protocol version 5.3. Stockholm: ECDC; 2016. Disponibil la: 
https://www.ecdc.europa.eu/sites/default/files/documents/PPS-HAI-AMR-protocol.pdf 
[accesat la 5.12.2019]. 
4. Friedrich AW. Control of hospital acquired infections and antimicrobial resistance in 
Europe: the way to go. Wien Med Wochenschr. 2019; 169(1): 25-30.  
5. Busuioc E, Cateriniuc N, Furtuna N, Rata V, Surdu Ş. Pilotarea studiului de prevalență de 
moment a infecțiilor asociate asistenței medicale și consumul antimicrobienelor în spitalele 
din Republica Moldova. Sănătate Publică, Economie şi Management în Medicină. 2019; 
4(82): 299-303.  
6. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati M, 
et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical 
research. Nat Rev Microbiol. 2019; 17(4): 203-218.  
7. Johnson AP. Methicillin-resistant Staphylococcus aureus: the European landscape. J 
Antimicrob Chemother. 2011; 66 Suppl 4: iv43-iv48.  
8. Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3,051 
Staphylococcus aureus isolates from 25 university hospitals participating in the European 
SENTRY study. J Clin Microbiol. 2001; 39(10): 3727-32.  
9. Stenhem M, Ortqvist A, Ringberg H, Larsson L, Olsson-Liljequist B, Haeggman S et al. 
Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Sweden 2000-
2003, increasing incidence and regional differences. BMC Infectious Diseases. 2006; 6:30.  
10. Friedrich AW. Control of hospital acquired infections and antimicrobial resistance in 
Europe: the way to go. Wien Med Wochenschr. 2019; 169(1): 25-30.  
11. Lakhundi S, Zhang K. Methicillin-Resistant Staphylococcus aureus: Molecular 
Characterization, Evolution, and Epidemiology. Clin Microbiol Rev. 2018; 31(4): e00020-
18.  
12. European Centre for Disease Prevention and Control. Surveillance of antimicrobial 
resistance in Europe 2016. Annual Report of the European Antimicrobial Resistance 
Surveillance Network (EARS-Net). Stockholm:ECDC; 2017. Disponibil la: 
https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-
europe-2017 [accesat 12 martie 2020].  
13. European Centre for Disease Prevention and Control. Surveillance of antimicrobial 
resistance in Europe. Annual Report of the European Antimicrobial Resistance Surveillance 
Network (EARS-Net) 2017. Stockholm:ECDC; 2018. Disponibil la: 
https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-




14. Global priority list of antibiotic- rezistant bacteria to guide research, discovery and 
development of new antibiotics. Geneva, World Health Organization, 2017. Disponibil la: 
https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-
bacteria/en/ [accesat la 10.06.2020]. 
15. Antimicrobial resistance: global report on surveillance 2014. Geneva, World Health 
Organization. Disponibil la: 
https://www.who.int/drugresistance/documents/surveillancereport/en/ [accesat 24 martie 
2019].  
16. Lee JYH, Monk IR, Gonçalves da Silva A, Seemann T, Chua KYL, Kearns A, et al. Global 
spread of three multidrug-resistant lineages of Staphylococcus epidermidis. Nat Microbiol. 
2018; 3(10): 1175-1185.  
17. Sahal G, Bilkay IS. Multi drug resistance in strong biofilm forming clinical isolates of 
Staphylococcus epidermidis. Braz J Microbiol. 2014; 45(2): 539-544.  
18. Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 
2014; 27(4):870-926.  
19. Longauerova A. Coagulase negative staphylococci and their participation in pathogenesis of 
human infections. Bratisl Lek Listy. 2006; 107(11-12): 448–452. 
20. Wernitz MH, Keck S, Swidsinski S, Schulz2 S, Veit1 K.  Cost analysis of a hospital-wide 
selective screening programme for MRSA carriers in the context of diagnostic related groups 
(DRG) payment. Clin Microbiol Infect.  2005; 11: 466-471 
21. Antonanzas F, Lozano C, Torres C. Economic features of antibiotic resistance: the case of 
methicillin-resistant Staphylococcus aureus. Pharmacoeconomics. 2015; 33: 285–325. 
22. Joo EJ, Park DA, Kang CI, Chung DR, Song JH, Lee SM, et al. Reevaluation of the impact 
of methicillin-resistance on outcomes in patients with Staphylococcus aureus bacteremia and 
endocarditis. Korean J Intern Med. 2019; 34(6): 1347-1362.  
23. Prisacari V, Buga D, Berdeu I. Aspecte epidemiologice în ulcerele trofice cu Staphylococcus 
meticilin-rezistent. One Health & Risk Management. 2021; 2: 51-57.  
24. Anderson DJ, Kaye KS, Chen LF, et al. Clinical and financial outcomes due to methicillin 
resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes 
study. PLoS One. 2009; 4(12): e8305.  
25. Thampi N, Showler A, Burry L, Bai AD, Steinberg M, Ricciuto DR, et al. Multicenter study 
of health care cost of patients admitted to hospital with Staphylococcus aureus bacteremia: 
Impact of length of stay and intensity of care. Am J Infect Control. 2015; 43(7):739-44. 
26. Diaz R, Afreixo V, Ramalheira E, Rodrigues C, Gago B. Evaluation of vancomycin MIC 
creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and 
meta-analysis. Clin Microbiol Infect. 2018; 24(2): 97-104.  
27. Almaş A, Flonta M, Petraşcu M, Năstase V. Sensibilitatea la antibiotice a tulpinilor de 
Staphylococcus aureus izolate din infecţii ale tegumentelor şi părţilor moi. Clujul Medical. 
2011; 84(2): 173-7. 
28. Prisacari V, Buga D, Berdeu I. Nosocomial infections with methicillin resistant 
Staphylococcus: epidemiogenic situation at day, solutions. AKADEMOS. 2017; 4(47): 72-
76. 
29. Balan G, Burduniuc O, Siniţîna I, Iasâbaş O, Bunescu I. Frecvenţa izolării tulpinilor de 
Staphylococcus aureus meticilino-rezistente în Republica Moldova. Buletin of the Academy 




30. Balan G., Covantev S., Cazacu-Stratu A. et al. Frequency of methicillin-resistant 
Staphylococcus aureus strains in healthcare associated infections in the Republic of 
Moldova. Romanian Archives of Microbiology and Immunology. 2017; 79-84.  
31. Galețchi P, Buiuc D, Plugaru Ș. Ghid de microbiologie medicală. 1997. pp. 44:81, 165:170. 
32. BioMerieux – diagnostics. Vitek 2 Compact. Disponibil pe: https://www.biomerieux-
diagnostics.com/vitekr-2-compact-0 [accesat: 19.06.2021]. 
33. Buiuc D, Neguț M. Tratat de microbilogie clinică. Ed. III, Editura medicală București, 2009, 
pp. 562-582. 




● Articles in international scientific journals abroad: 
 articles in ISI, SCOPUS and other international databases * 
1.  Буга Д., Присакарь В. Значимость метициллин-резистентных стафилококков в 
септической патологии. B: Медицинский альманах. 2019; 1: 40-43. ISSN: 1997-
7689. doi: 10.21145/2499-9954-2019-1-40-43 (IF:0,47). 
2. Prisacari V., Buga D. Epidemiology of purulent-septic infections caused by methicillin-
resistant Staphylococcus in the Republic of Moldova. In: The Medical-Surgical Journal 
(în tipar). E-ISSN: 2286-2560 (IF: 1.044). 
3. Присакарь В., Буга Д., Сава В. Внутрибольничные инфекции вызванные 
метициллинрезистентными стафилакокками (MRS). B: Журнал МедиАль. 2018; 2: 
8-11 ISSN 2225-0026 (IF: 0,356). 
4. Присакарь В., Буга Д. Проблемa роста антибиотикорезистентности 
микроорганизмов рода Staphylococcus. B: Журнал МедиАль. 2020;(2):55. ISSN 
2225-0026 (IF: 0,356). 
 
● Articles in accredited national scientific journals: 
 articles in category B journals  
5. Prisacari V., Buga D., Berdeu I. Infecțiile nosocomiale cu Staphylococcus meticilino-
rezistent: situația epidemiogenă la zi, soluții. În: AKADEMOS. 2017; 4: 72-77. ISSN 
1857-0461 
6. Buga D., Prisacari V., Berdeu I., Balica I., Sinițîna I., Manica L., Rusu V. Situația 
epidemiogenă prin infecții cu Staphylococcus meticilin-rezistent în Republica Moldova. 
În:  Sănătate publică, Economie şi Management în Medicină. 2019; 4 (82): 294-299. 
ISSN 1857-0461 
7. Buga D. Problema creșterii rezistenței la preparatele antibacteriene a tulpinilor de 
Staphylococcus. În: Sănătate publică, Economie şi Management în Medicină. 2020; 5 
(87): 26-31. ISSN 2587-3873 
8. Buga D. Infecțiile septico-purulente cu Staphylococcus meticilin-rezistent: articol de 
sinteză. In: Moldovan Journal of Health Sciences (Revista de Ştiinţe ale Sănătăţii din 
Moldova). (în tipar).  
  
● Articles in journals under the process of accreditation: 
9. Prisacari V., Buga D., Berdeu I. Aspecte epidemiologice în ulcerele trofice cu 






● Abstracts in the proceedings of national and international scientific conferences 
10. Buga D. Aspecte epidemiologice a infecțiilor nosocomiale septice cauzate de 
Staphylococcus meticilino-rezistent (MRS). În: Volum de rezumate a manifestărilor 
științifice, zilele U.M.F din Craiova a XLIX-a ediţie, Editura Universitară Craiova; 2019, 
p. 75. 
11. Buga D. Incidența prin infecții nosocomiale cu Staphylococcus meticilin-rezistent în 
Republica Moldova. În: Culegere de rezumate științifice ale studenților, rezidenților și 
tinerilor cercetători, USMF „Nicolae Testemiţanu”. Chișinău; 2019, p. 36. 
12. Буга Д. Чувствительность к антибиотикам штаммoв Staphylococcus метициллин-
устойчивых в родовспомогательных стационарaх. B: Мікробіологія, вірусологія та 
імунологія в сучасній клінічній і лабораторній медицині, Xapkiв; 2020, c.15. 
13. Buga D. Epidemiogenic situation by infection with methicillin-resistant Staphylococcus 
in Republic of Moldova. In: Abstract book, MedEspera 2020: The 8th International 
Medical Congress for Students and Young Doctors, Chişinău; 2020. p. 305. 
14. Buga D. Problema creșterii rezistenței la preparatele antibacteriene a tulpinilor de 
Staphylococcus. În: Culegere de rezumate științifice ale studenților, rezidenților și 
tinerilor cercetători. USMF „Nicolae Testemiţanu; Chișinău; 2020, p. 169. 
15. Buga D. Prisacari V. Infecțiile cu Staphylococcus meticilino-rezistent în spitalele 
multiprofil, în dinamica multianuală n: Culegere de rezumate științifice ale studenților, 
rezidenților și tinerilor cercetători. USMF „Nicolae Testemiţanu; Chișinău; 2021. 
● Participation with papers in scientific forums: 
 International forums  
16. Буга Д. В., Присакарь В. И. Роль метициллин-резистентных стафилококков в 
септической патологии. Всероссийская научно-практическая конференция 
специалистов по контролю ИСМП „Инфекции, связанные с оказанием 
медицинской помощи — междисциплинарный подход к профилактике” с 
международным участием. Екатеринбург, 24-25 апреля 2019. 
17. Buga D. Aspecte epidemiologice a infecțiilor nosocomiale septice cauzate de 
Staphylococcus meticilino-rezistent (MRS)”. Conferința științifică anuală în cadrul 
Zilelor U.M.F din Craiova a XLIX-a ediţie. Craiova 7-8 iunie, 2019. 
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